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a codon-position-speciﬁc HKY substitution model was used.
Results show that all three pandemic inﬂuenza strains
of the 20th century, plus to 2009 H1N1 pandemic virus,
were generated through a series of multiple reassortment
events and emerged over a period of years before pandemic
recognition. The results also indicated that each of the 20th-
Century pandemic strains was produced by reassortment
between the previously circulating human virus and at least
one virus of animal origin. The novel gene segments for
the H2N2/1957 and H3N2/1968 pandemics seem to have
originated from avian hosts, but the zoonotic sources
of the introduced viral gene segments for the 1918
pandemic remain ambiguous. Evidence suggests that, over
a number of years, avian gene virus segments entered
mammalian populations where the viruses may have
undergone reassortment with the prevailing human virus.
Given the frequent interspecies transmission of inﬂuenza
viruses between swine and humans, it is most likely
that such reassortment events occurred in swine before
pandemic emergence. This scenario is precisely describes
the emergence of the 2009 H1N1 virus which involved a
series of reassortment events in pigs that involved viruses
of avian, swine and human origin.
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Inﬂuenza causes annual recurrent health impact on
the society. In Hong Kong, about 130 580 per 100,000
elderly individuals are hospitalized annually for inﬂuenza-
associated complications such as pneumonia, exacerbation
of chronic obstructive pulmonary diseases or asthma,
and acute cardiovascular events. While antiviral agents
speciﬁc for inﬂuenza have been available for many years,
the practice of antiviral treatment for these hospitalized
patients still varies from centre to centre. On one extreme,
the duration of 48 hours after illness onset is still regarded
as the “cut-off” for cost-effective treatment. Whereas, in
view of the often higher viral load and prolonged shedding
of viruses seen in patients with severe disease, some
clinicians would offer treatment even beyond the golden
period of “48 hours”. We have shown that treatment with
neuraminidase inhibitor for the high-risk group hospitalized
for laboratory conﬁrmed seasonal inﬂuenza could accelerate
viral clearance, shorten viral shedding, reduce the length
of hospital stay, allow earlier discontinuation of oxygen
therapy and decrease mortality. For instance, we have
shown that initiation of oseltamivir within 96 hours after
illness onset was associated independently with a decrease
in mortality (OR: 0.26, 95%CI: 0.08 0.87).
Our experience from the 2009 pandemic suggested that
patients with severe pneumonia often had a higher viral
load at presentation (1.3 logs higher than those with
mild infection), and most of them had viral RNA detected
from extrapulmonary sites. Clinical recovery was associated
with rapid viral clearance following a standard course of
neuraminidase inhibitor treatment. However, patients with
severe pneumonia often exhibited a prolonged course of
viral shedding, especially from the lower respiratory tract,
despite the administration of neuraminidase inhibitor. This
raised the consideration of higher dose and more sustained
antiviral regime for selected high-risk patients.
The development of drug resistance for a highly mutable
virus like inﬂuenza is always a concern. The older class of
anti-inﬂuenza agent, adamantanes, is well known for such
problem. Given the known resistance of the 2009 pandemic
H1N1 virus to this class of anti-inﬂuenza compounds,
the choice of treatment and prophylaxis is limited to
neuraminidase inhibitors. While a huge number of doses
of neuraminidase inhibitors, mainly oseltamivir and to a
small extent zanamivir, have been administered during
the pandemic; resistance remains at a low level as what
one would expect from the natural mutation of this virus.
Majority of the reported cases of neuraminidase inhibitor-
resistance were from low-dose or prolong administration in
immunosuppressed patients.
The administration of effective antiviral compounds remains
an important component in the clinical management of
inﬂuenza infection, especially for those with a high risk of
developing severe complications.
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Hepatitis B Virus (HBV) has evolved a unique life cycle that
results in the production of enormous viral loads during
active replication without actually killing the infected cells
directly. Two of the key events in the viral life cycle of
HBV involve ﬁrstly the generation of a covalently closed
circular (ccc) DNA transcriptional template either from input
genomic DNA or newly replicated capsid-associated DNA and
secondly, reverse transcription of the viral pregenomic RNA
to form progeny HBV DNA genomes. New data are emerging
regarding the epigenetic control of cccDNA which may
represent another key factor involved in the pathogenesis
and natural history of the disease. A high rate of viral
turnover, combined with an error-prone polymerase, results
in a very high frequency of mutational events during
HBV replication. Not surprisingly then, particular selection
pressures, both endogenous (host immune clearance) and
exogenous (vaccines and antiviral drugs), readily select out
escape mutants.
Antiviral drug resistance is associated with point mutations
in the HBV polymerase/reverse transcriptase (rt) and ﬁve
major “pathways” of antiviral drug-resistance associated
substitutions have now been identiﬁed. The ﬁrst is
the rtM204V/I pathway which is selected out by the
L-nucleosides Lamivudine (LMV) and Telbivudine (LdT). The
second is the rtA181T/V pathway selected by both the
L-nucleosides as well as the Acyclic Phosphonates Adefovir
(ADV) and Tenofovir (TFV) and is also referred to as
the “Shared Pathway”. The third or rtN236T pathway is
associated with resistance to ADV and reduced sensitivity to
TFV whilst the double mutant, rtA181T/V+rtN236T, in the
double resistance pathway which has been recently linked
to TFV resistance as well as ADV treatment failure. The ﬁfth
or the D-Cyclopentane pathway is associated with entecavir
resistance and typically requires at least three changes:
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rtM204V/I+rtL180M plus rtI169T or rtT184G or rtS202I or
rtM250V.
In the clinical context of antiviral drug resistance, treating
physicians need to adopt therapeutic strategies that
effectively control viral replication in the ﬁrst place, but
if treatment failure does occur, then a knowledge of cross-
resistance is needed in order to tailor appropriate “add-on”
therapy. Finally, the role of host genetics in inﬂuencing the
outcome of HBV disease in the context of natural history and
therapy is beginning to aid understanding in pathogenesis
and, when this knowledge is linked to pathogen-speciﬁc
databases, this should translate into more individualised
and effective patient care.
Concurrent Session 10: Management of CHB
Factors and Trends
Saturday, July 16, 2011, 13:30 15:00
Meeting Room 310
CS10.1 Current approaches and potential strategies:
Avoid and manage drug resistance
Abstract not available
CS10.2 HBsAg seroconversion as treatment endpoint:
Phenomenon and reality
J.L. Hou*. Hepatology Unit, Nanfang Hospital, Guangzhou,
China
Abstract not available
CS10.3 A better clinical practice through quantitative
HBsAg levels
J.Y. Park*. Department of Internal Medicine, Yonsei
University College of Medicine; Liver Cirrhosis Clinical
Research Center, Seoul, Korea
Despite the availability of effective vaccines, chronic
hepatitis B (CHB) remains a signiﬁcant health burden
worldwide. In clinical ﬁelds, hepatitis B surface antigen
(HBsAg) has long served as a qualitative diagnostic marker
for HBV infection. HBsAg seroclearance is considered the
closest-to-cure outcome of hepatitis B virus infection,
reﬂecting immunological control of infection. Recently,
retrospective and prospective studies have shown that
HBsAg levels change along the natural history of CHB, and
that HBsAg levels in patients undergoing antiviral therapy
suggest a role for HBsAg quantitation in monitoring response
to therapy. There is increasing evidence that baseline
HBsAg levels and HBsAg kinetics during antiviral therapy
are predictive of treatment result. Notably, advances have
been made in the development of quantitative HBsAg assays,
which have allowed viral replication monitoring, and there
is an opportunity to make maximal use of quantitative HBsAg
to elucidate its role in clinical ﬁelds. Quantitative HBsAg
appear to be very promising as baseline and early on-
treatment predictors of sustained viral suppression and
HBsAg clearance. Further studies are required to validate
the use of these tools.
CS10.4 The cost effectiveness of various strategies for
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In order to meet the global target of controlling tuberculosis
(TB), much emphasis has been placed on the development of
new tools for the purpose, to complement the enhancement
of existing programmatic activities in various countries
and geographical regions worldwide. The development of
new tools can be divided into 4 main areas. The ﬁrst
area is concerned with advances in the diagnosis of
TB and rapid assessment of drug susceptibility of the
Mycobacterium tuberculosis strains causing the disease.
The new tools developed ultilize the molecular approach or
phenotypic methods. A quite signiﬁcant recent development
has been that of a commercially available tool that rapidly
detects the presence of M. tuberculosis in the sputum
specimen, alongside performance of drug susceptibility
testing, especially to rifampicin. This apparently robust
test requires minimal manual skill, and appears readily
applicable at the point of care. However, it is clear
that the availability of new diagnostic tools does not
necessarily equate to their adoption, the translation of
policy into practice requires identiﬁcation of obstacles
and their resolution. Regarding the development of new
anti-tuberculosis drugs which constitutes the second area,
quite a number of new compounds are on the horizon.
Several are in Phase II and Phase III of clinical trials. Aside
from the rifamycins already in use, the diarylquinoline,
nitroimidazoles and the newer ﬂuoroquinolones appear to
hold the highest promise for clinical application in TB
treatment in the near future. Other potentially useful
compounds might include the ethylenediamines and the
oxazolidinones. Despite the encouraging progress, there
remains the important challenge of lack of global clinical
trial capacity to support the new drugs developed to gain
timely registration. The third area is clearly related to
TB vaccine development. The only TB vaccine available
for use today is bacillus Calmette Guerin which needs
improvement. There is an urgent need for developing a
modern, safe and effective TB vaccine to prevent all
forms of disease, in all age groups and among people
with HIV infection. Several vaccine candidates are now
in Phase II clinical development. The most promising ones
appear to be the recombinant forms of BCG, other live
mycobacterial vaccines and vaccines based on genetic
attenuation of M. tuberculosis. The last area is connected
with the development of biomarkers for monitoring disease
activity and predicting the outcome of TB treatment.
The advancement in this area has been relatively tardy.
Hopefully a combination of biomarkers might address the
issue better. It is clear that much more work is still required
here. Thus the past decade has witnessed a renaissance of
activities in the development of new tools for achieving
TB control globally. The fruitful outcome of these activities
have furnished high hopes for better control of TB, the
formidable foe of mankind, in the decade to come.
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Efforts to control the global TB epidemic have been
hampered by the lack of accurate and rapid diagnostic
